目的 观察重组人表皮生长因子滴眼液在全激光经角膜上皮的角膜切削术(TransPRK)术后的临床疗效观察.方法 选取行TransPRK手术60例病人(120只眼),采用硬币法分成观察组和对照组.观察组在常规用药的基础上加用重组人表皮生长因子滴眼液(用药频次为4次每天,1次1滴,时间为持续1周),对照组常规用药.术后于第1天、第2天、第3天、第1个月、第2个月、第3个月时分别评价疼痛、异物感、角膜上皮愈合情况、裸眼视力、角膜上皮下雾状混浊(Haze)、残余等效球镜度(MRSE)指标.结果 除Haze指标外,其它指标的时间点观察值均差异有统计学意义(P<0.05).两组间疼痛、角膜上皮愈合在第2天、第3天差异有统计学意义(P<0.008 3,α'=0.05/6=0.008 3),观察组评分均低于对照组评分;裸眼视力指标在第2天、第3天差异有统计学意义(P<0.008 3,α'=0.008 3),且观察组评分(4.40±0.12)、(4.83±0.12)均高于对照组评分(4.33±0.12)、(4.76±0.14);其它观察指标均差异无统计学意义.结论 重组人表皮生长因子滴眼液能够改善TransPRK术后病人的早期部分疼痛症状,能够促进角膜上皮的愈合,提高早期视力,对异物感、Haze、MRSE均无影响.%Objective To investigate the clinical efficacy of Recombinant Human Epidermal Growth Factor Eye Drops (Yi Bei,rhEGF) after TransPRK surgery.Methods Sixty patients (120 eyes) after TransPRK surgery were randomly assigned into the observation group and control group by coin method.On the basis of routine treatment,the observation group was added with Recombinant Human Epidermal Growth Factor Eye Drops (The use frequency is 4 times / day,1 times 1 drop,the time for a week).After operation respectively in D1,D2,D3,m1,m2,m3 were evaluated pain,foreign body sensation,corneal epithelial healing,uncorrected visual acuity,Haze and manifest refractive spherical equivalent (MRSE) index.Results In addition to Haze indicators,other indicators of the time differences were statistically significant (P<0.05).Between the two groups of pain,healing of corneal epithelium were statistically significant in D2,D3 difference (P<0.008 3,α'=0.05/6=0.008 3),TG score was lower than the CG score.the uncorrected visual acuity index was statistically significant in D2,D3 difference (P<0.008 3,α'=0.008 3),and the TG score (4.40±0.12,4.83±0.12) was higher than that of CG (4.33±0.12,4.76±0.14),and other indexes were not statistically significant.Conclusions rhEGF eye drops not only can improve early postoperative TransPRK patient's partly symptoms of pain,but also can promote corneal epithelial healing and improve early visual acuity.
展开▼
